Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 4
1966 2
1967 3
1968 2
1969 7
1970 3
1971 3
1972 6
1973 4
1974 5
1975 3
1976 2
1977 4
1978 1
1979 3
1980 3
1981 3
1982 7
1983 3
1984 11
1985 10
1986 10
1987 6
1988 10
1989 17
1990 12
1991 11
1992 16
1993 10
1994 20
1995 10
1996 7
1997 10
1998 4
1999 13
2000 13
2001 13
2002 27
2003 22
2004 34
2005 22
2006 29
2007 18
2008 21
2009 29
2010 25
2011 28
2012 19
2013 20
2014 14
2015 13
2016 18
2017 25
2018 16
2019 8
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

631 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2
Feagan BG, et al. J Crohns Colitis 2018 - Clinical Trial. PMID 29471381 Free PMC article.
Similarly, VDZ/VDZ-treated patients had faster time to fistula closure and were more likely to have fistula closure at Week 52 [33% vs 11%; HR: 2.54; 95% CI, 0.54-11.96]. Prior failure of antibiotic therapy was a negative predictor of fistula closure [HR: 0.217; 95% CI, 0.059-0.795; p = 0.021], whereas trough vedolizumab concentrations did not affect closure rates. ...
Similarly, VDZ/VDZ-treated patients had faster time to fistula closure and were more likely to have fistula closure at Week 52 …
Digestive system fistula: a problem still relevant today.
Głuszek S, et al. Pol Przegl Chir 2011. PMID 22166240
The causes of the occurrence of digestive system fistula, methods and results of treatment were analyzed. RESULTS. The analysis covered 32 patients with digestive system fistula, among them 15 men and 17 women. ...Yet, digestive system fistula as a serious complication still poses a very difficult surgical problem....
The causes of the occurrence of digestive system fistula, methods and results of treatment were analyzed. RESULTS. The …
Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.
Yarur AJ, et al. Aliment Pharmacol Ther 2017. PMID 28211593 Free article.
BACKGROUND: Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn's disease, even though some patients do not benefit from therapy. ...The primary outcome was fistula healing defined as the absence of drainage. The secondary outcome was complete fistula closure and mucosal healing. ...
BACKGROUND: Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn's disease, even though some pat …
Infliximab maintenance therapy for fistulizing Crohn's disease.
Sands BE, et al. N Engl J Med 2004 - Clinical Trial. PMID 14985485 Free article.
BACKGROUND: Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab is an effective maintenance therapy for patients with fistulas. METHODS: We performed a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of infliximab maintenance therapy in 306 adult patients with Crohn's disease and one or more draining abdominal or perianal fistulas of at least three months' duration. ...
BACKGROUND: Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Cr …
Effect of Oral ω3-Polyunsaturated Fatty Acids as a Complement Management to Control Fistula Output and Inflammation in Patients With Digestive Fistula.
Martínez-Ordaz JL, et al. J Gastrointest Surg 2017. PMID 27909869
BACKGROUND: The presence of digestive fistula involves chronic inflammation and fibrosis. It has been reported that ω3-polyunsaturated fatty acids stimulate the resolution of inflammation. AIM: Determine if the administration of oral ω3 reduces fistula output and the time required for fistula closure. METHODS: Forty-nine patients with postoperative fistula were randomly divided in two groups: 26 received conventional treatment and 23 received the conventional treatment supplemented with ω3 (540 mg eicosapentaenoic acid and 360 mg docosahexaenoic acid) for 35 days. ...
BACKGROUND: The presence of digestive fistula involves chronic inflammation and fibrosis. It has been reported that ω3-polyuns …
[Efficacy of over-the-scope clip for gastrointestinal fistula].
Wang G, et al. Zhonghua Wei Chang Wai Ke Za Zhi 2017. PMID 28105625 Chinese.
OBJECTIVE: To explore the efficacy of over-the-scope clip (OTSC) in the treatment of gastrointestinal fistula. METHODS: Clinical data of 12 gastrointestinal fistula patients, including 3 internal fistula and 9 external fistula treated with OTSC in our institute from March 2015 to May 2016 were retrospectively analyzed. ...According to comprehensive evaluation, including drainage without digestive juices, no recurrence of intra-abdominal infection, no overflow of contrast medium during digestive tract radiography, and CT examination without intra-abdominal abscess, clinical gastrointestinal fistula closure was 91.7%(11/12). ...
OBJECTIVE: To explore the efficacy of over-the-scope clip (OTSC) in the treatment of gastrointestinal fistula. METHODS: Clinical data …
Photodynamic therapy for the treatment of complex anal fistula.
Arroyo A, et al. Tech Coloproctol 2017. PMID 28108825
BACKGROUND: Photodynamic therapy (PDT) is a new procedure for the treatment of anal fistula. This preliminary study was designed to investigate the safety and effectiveness of this new technique in the treatment of anal fistula. ...Intralesional 5-aminolevulinic acid (ALA) 2% was directly injected into the fistula. The internal and external orifices were closed. ...
BACKGROUND: Photodynamic therapy (PDT) is a new procedure for the treatment of anal fistula. This preliminary study was design …
Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.
Papamichael K and Cheifetz AS. World J Gastroenterol 2017. PMID 28974885 Free PMC article.
Nevertheless, current data suggest that sustained remission and long-term complete fistula healing can be achieved in only 30% to 50% of patients. ...This suggests that therapeutic drug monitoring and a treat-to-trough therapeutic approach may emerge as the new standard of care for optimizing anti-TNF therapy in patients with perianal fistulising CD....
Nevertheless, current data suggest that sustained remission and long-term complete fistula healing can be achieved in only 30% to 50% …
Thermoresponsive Gel Embedded with Adipose Stem-Cell-Derived Extracellular Vesicles Promotes Esophageal Fistula Healing in a Thermo-Actuated Delivery Strategy.
Silva AKA, et al. ACS Nano 2018. PMID 30231208
Herein, we explore another potential EV therapeutic application, fistula healing, together with a local minimally invasive delivery strategy. Allogenic extracellular vesicles (EVs) from adipose tissue-derived stromal cells (ASCs) are administered in a porcine fistula model through a thermoresponsive Pluronic F-127 (PF-127) gel, injected locally at 4 °C and gelling at body temperature to retain EVs in the entire fistula tract. ...
Herein, we explore another potential EV therapeutic application, fistula healing, together with a local minimally invasive delivery s …
631 results
Jump to page
Feedback